Actively Recruiting
Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease
Led by China-Japan Friendship Hospital · Updated on 2024-07-16
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are exploring how often coronary microvascular dysfunction occurs and how it affects the outlook for patients who have stable chest pain symptoms but do not have significant blockages in their large coronary arteries. These patients are candidates for invasive coronary angiography, and the study focuses on those with fractional flow reserve (FFR) values greater than 0.80, indicating no major artery narrowing. This observational study aims to better understand this condition in people with non-obstructive coronary artery disease. This study involves observing patients who meet the criteria without giving any experimental treatments. Participants will be monitored over time to see the incidence of coronary microvascular dysfunction and how it influences the risk of major adverse cardiovascular events (MACE) over 12 months. The study does not involve treatment assignment but collects data from patients undergoing routine clinical evaluation. Participants will be followed for at least 12 months to assess the occurrence of major adverse cardiovascular events. The study collects clinical data from invasive coronary angiography and tracks patient outcomes over time. Researchers aim to learn more about the prognosis of patients with stable angina and non-obstructive coronary artery disease, helping guide future care and management strategies.
CONDITIONS
Brief Title
Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Have stable anginal symptoms and are clinically indicated for invasive coronary angiography
- No hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) greater than 0.80
You will not qualify if you...
- Recent acute myocardial infarction
- Significant valvular heart disease
- Advanced chronic kidney disease
- Significant epicardial coronary artery stenosis (>70% in major vessels) requiring percutaneous coronary intervention
- Unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants undergo diagnostic procedures to assess coronary microvascular function and confirm absence of significant coronary artery disease.
1 to 2 visits depending on diagnostic procedures
Duration - 12 months
Participants are monitored for major adverse cardiac events over a 12-month period.
Periodic visits during the 12 months for assessments
Trial Site Locations
Total: 1 location
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
Z
Zhaoxue Sheng, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here